Skip to Content
Discovering the causes of cancer and the means of prevention

Publications Search - Abstract View

Title: Combined genetic and splicing analysis of BRCA1 c.[594-2A>C; 641A>G] highlights the relevance of naturally occurring in-frame transcripts for developing disease gene variant classification algorithms.
Authors: de la Hoya M,  Soukarieh O,  López-Perolio I,  Vega A,  Walker LC,  van Ierland Y,  Baralle D,  Santamariña M,  Lattimore V,  Wijnen J,  Whiley P,  Blanco A,  Raponi M,  Hauke J,  Wappenschmidt B,  Becker A,  Hansen TV,  Behar R,  Investigators K,  Niederacher D,  Arnold N,  Dworniczak B,  Steinemann D,  Faust U,  Rubinstein W,  Hulick PJ,  Houdayer C,  Caputo SM,  Castera L,  Pesaran T,  Chao E,  Brewer C,  Southey MC,  van Asperen CJ,  Singer CF,  Sullivan J,  Poplawski N,  Mai P,  Peto J,  Johnson N,  Burwinkel B,  Surowy H,  Bojesen SE,  Flyger H,  Lindblom A,  Margolin S,  Chang-Claude J,  Rudolph A,  Radice P,  Galastri L,  Olson JE,  Hallberg E,  Giles GG,  Milne RL,  Andrulis IL,  Glendon G,  Hall P,  Czene K,  Blows F,  Shah M,  Wang Q,  Dennis J,  Michailidou K,  McGuffog L,  Bolla MK,  Antoniou AC,  Easton DF,  Couch FJ,  Tavtigian S,  Vreeswijk MP,  Parsons M,  Meeks HD,  Martins A,  Goldgar DE,  Spurdle AB
Journal: Hum Mol Genet
Date: 2016 Jun 1
Branches: CGB
PubMed ID: 27008870
PMC ID: PMC5081057
Abstract: A recent analysis using family history weighting and co-observation classification modeling indicated that BRCA1 c.594-2A > C (IVS9-2A > C), previously described to cause exon 10 skipping (a truncating alteration), displays characteristics inconsistent with those of a high risk pathogenic BRCA1 variant. We used large-scale genetic and clinical resources from the ENIGMA, CIMBA and BCAC consortia to assess pathogenicity of c.594-2A > C. The combined odds for causality considering case-control, segregation and breast tumor pathology information was 3.23 × 10(-8) Our data indicate that c.594-2A > C is always in cis with c.641A > G. The spliceogenic effect of c.[594-2A > C;641A > G] was characterized using RNA analysis of human samples and splicing minigenes. As expected, c.[594-2A > C; 641A > G] caused exon 10 skipping, albeit not due to c.594-2A > C impairing the acceptor site but rather by c.641A > G modifying exon 10 splicing regulatory element(s). Multiple blood-based RNA assays indicated that the variant allele did not produce detectable levels of full-length transcripts, with a per allele BRCA1 expression profile composed of ≈70-80% truncating transcripts, and ≈20-30% of in-frame Δ9,10 transcripts predicted to encode a BRCA1 protein with tumor suppression function.We confirm that BRCA1c.[594-2A > C;641A > G] should not be considered a high-risk pathogenic variant. Importantly, results from our detailed mRNA analysis suggest that BRCA-associated cancer risk is likely not markedly increased for individuals who carry a truncating variant in BRCA1 exons 9 or 10, or any other BRCA1 allele that permits 20-30% of tumor suppressor function. More generally, our findings highlight the importance of assessing naturally occurring alternative splicing for clinical evaluation of variants in disease-causing genes.